

Hoving, J. W. et al. (2018) Volumetric and spatial accuracy of CTP estimated ischemic core volume in patients with acute ischemic stroke. Stroke, 49(10), pp. 2368-2375.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

http://eprints.gla.ac.uk/161651/

Deposited on: 12 June 2018

Enlighten – Research publications by members of the University of Glasgow\_ http://eprints.gla.ac.uk

1	Volumetric and spatial accuracy of CTP estimated ischemic core volume in	
2	patients with acute ischemic stroke	
3		
4	Jan W. Hoving <sup>1,2</sup> , Henk A. Marquering PhD <sup>2,3</sup> , Charles B.L.M. Majoie MD <sup>2</sup> , Nawaf Yassi	
5	PhD <sup>1,4</sup> , Gagan Sharma MCA <sup>1</sup> , David S. Liebeskind MD <sup>5</sup> , Aad van der Lugt MD <sup>6</sup> , Yvo B.	
6	Roos MD <sup>7</sup> , Wim van Zwam MD <sup>8</sup> , Robert J. van Oostenbrugge MD <sup>9</sup> , Mayank Goyal MD <sup>10</sup> ,	
7	Jeffrey L. Saver MD <sup>11</sup> , Tudor G. Jovin MD <sup>12</sup> , Gregory W. Albers MD <sup>13</sup> , Antoni Davalos	
8	MD <sup>14</sup> , Michael D. Hill MD <sup>15</sup> , Andrew M. Demchuk MD <sup>15</sup> , Serge Bracard MD <sup>16</sup> , Francis	
9	Guillemin PhD <sup>17</sup> , Keith W. Muir PhD <sup>18</sup> , Philip White MD <sup>19</sup> , Peter J. Mitchell MMed <sup>20</sup> ,	
10	Geoffrey A. Donnan MD <sup>4</sup> , Stephen M. Davis MD <sup>1</sup> , Bruce C.V. Campbell PhD <sup>1</sup>	
11		
12		
13	1. Department of Medicine and Neurology, Melbourne Brain Centre at the Royal	
14	Melbourne Hospital, University of Melbourne, Parkville, Australia	
15	2. Department of Radiology and Nuclear Medicine, Academic Medical Center,	
16	Amsterdam, the Netherlands	
17	3. Department of Biomedical Engineering and Physics, Academic Medical Center,	
18	Amsterdam, the Netherlands	
19	4. The Florey Institute of Neuroscience and Mental Health, University of Melbourne,	
20	Parkville, Australia	
21	5. Neurovascular Imaging Research Core, Department of Neurology, University of	
22	California at Los Angeles, Los Angeles, California, USA	
23	6. Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical	
24	Center Rotterdam, the Netherlands	
25	7. Department of Neurology, Academic Medical Center, Amsterdam, the Netherlands	

26	8.	Department of Radiology, Maastricht University Medical Center and Cardiovascular
27		Research Institute (CARIM), Maastricht, the Netherlands
28	9.	Department of Neurology, University Medical Center (MUMC) and Cardiovascular
29		Research Institute Maastricht (CARIM), Maastricht, the Netherlands
30	10	Department of Radiology, University of Calgary, Foothills Hospital, Calgary AB,
31		Canada
32	11.	. Department of Neurology, University of California Los Angeles, Los Angeles,
33		California, USA
34	12	Stroke Institute, Department of Neurology, University of Pittsburgh Medical Center,
35		Pittsburgh
36	13	Stanford Stroke Center, Stanford University, Stanford, California, USA
37	14	. Department of Neuroscience, Hospital Germans Trias i Pujol, Universitat Autònoma
38		de Barcelona, Barcelona, Spain
39	15	Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of
40		Medicine, University of Calgary, Foothills Hospital, Calgary AB, Canada
41	16	Department of Diagnostic and Interventional Neuroradiology, INSERM U 947,
42		University of Lorraine and University Hospital of Nancy, Nancy, France
43	17.	. INSERM CIC-EC 1433 Clinical Epidemiology, University of Lorraine and University
44		Hospital of Nancy, Nancy, France
45	18	. Institute of Neuroscience & Psychology, University of Glasgow, Queen Elizabeth
46		University Hospital, Glasgow G51 4TF, Scotland, UK.
47	19	. Institute of Neuroscience, Newcastle University and Dept. of Neuroradiology,
48		Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
49	20	Department of Radiology, Royal Melbourne Hospital, University of Melbourne,
50		Melbourne, Australia

```
51 Cover title: Accuracy of CTP estimated ischemic core volume
```

- 53 Keywords: ischemic stroke; stroke; endovascular treatment; computed tomography; magnetic
- 54 resonance imaging
- 55
- 56 Word Count: 5128 (Abstract 271)
- 57
- 58 Corresponding Author:
- 59 A/Prof Bruce Campbell, Dept Neurology, Royal Melbourne Hospital, Parkville 3050,
- 60 Australia
- 61 Tel: +61-3-9342-8448 Fax: +61-3-9342-8427
- 62 Email: bruce.campbell@mh.org.au

64 Abstract65

#### 66 Background and Purpose

The volume of estimated ischemic core using computed tomography perfusion (CTP) imaging
can identify ischemic stroke patients who are likely to benefit from reperfusion, particularly
beyond standard time windows. We assessed the accuracy of pre-treatment CTP estimated
ischemic core in patients with successful endovascular reperfusion.

71

#### 72 *Methods*

Patients from the HERMES and EXTEND-IA TNK databases who had pre-treatment CTP,
>50% angiographic reperfusion, and follow-up MRI at 24h were included. Ischemic core
volume on baseline CTP data was estimated using relative cerebral blood flow <30%</li>
(RAPID, iSchemaView). Follow-up diffusion MRI was registered to CTP and the diffusion
lesion was outlined using a semi-automated algorithm. Volumetric and spatial agreement
(using Dice similarity co-efficient, Average Hausdorff Distance and precision) were assessed
and expert visual assessment of quality performed.

80

#### 81 *Results*

In 120 patients, median CTP estimated ischemic core volume was 7.8(IQR 1.8-19.9)ml and median diffusion lesion volume at 24h was 30.8(IQR 14.9-67.6)ml. Median volumetric difference was 4.4(IQR 1.2-12.0)ml. Dice similarity coefficient was low (median 0.24, IQR 0.15-0.37). The median precision (positive predictive value) of 0.68(IQR 0.40-0.88) and Average Hausdorff Distance (median 3.1, IQR 1.8-5.7mm) indicated reasonable spatial agreement for regions estimated as ischemic core at baseline. Overestimation of total ischemic core volume by CTP was uncommon. Expert visual review revealed overestimation

89 predominantly in white-matter regions.

### 90 *Conclusion*

- 91 CTP estimated ischemic core volumes were substantially smaller than follow-up DWI lesions
- 92 at 24h despite endovascular reperfusion within 2h of imaging. This may be partly due to
- 93 infarct growth. Volumetric CTP core overestimation was uncommon and not related to
- 94 imaging-to-reperfusion time. Core overestimation in white-matter should be a focus of future
- 95 efforts to improve CTP accuracy.

96

#### 98 Introduction

Early reperfusion in acute ischemic stroke is the key to reducing disability.<sup>1</sup> Multiple 99 randomized trials<sup>2-8</sup> have shown that endovascular thrombectomy reduces disability versus 100 standard care within 6h of stroke onset. The DAWN<sup>9</sup> and DEFUSE3<sup>10</sup> trials have successfully 101 102 used imaging selection based on CTP or MRI processed with RAPID software 103 (iSchemaView, Mountain View, CA, USA) to identify patients >6h after last known well time who benefit from reperfusion. Although analyses of 0-6h data have not shown an interaction 104 105 between CTP core volume and the treatment effect of endovascular thrombectomy, CTP may have diagnostic and prognostic value for patients within 6h.<sup>11-13</sup> Several studies assessing 106 107 contemporaneous CTP and diffusion-weighted MRI (MR-DWI) have shown reasonable agreement in estimates of the extent of permanently injured tissue.<sup>14,15</sup> However, CTP results 108 have varied between post-processing techniques and thresholds applied by different 109 software.11,16,17 110

111

112 Although CTP is fast and easily accessible in the acute setting of ischemic stroke, it is 113 recognized that cerebral blood flow (CBF) map segmentations tend to include false-positive regions in areas of hypodense white-matter (leukoaraiosis).<sup>18</sup> CBF is physiologically lower in 114 white versus grey-matter and further reduced in regions of leukoaraiosis.<sup>18</sup> Given DAWN and 115 116 DEFUSE3 results, standardized CTP post-processing software with validated thresholds is likely to be increasingly used clinically to select patients for reperfusion therapies beyond 117 118 standard therapeutic time windows. A crucial question, therefore, is how reliable CTP estimates of irreversible injury are in the current endovascular paradigm of fast reperfusion.<sup>19</sup> 119 120 121 We aimed to assess the volumetric and spatial agreement of estimated ischemic core on CTP

122 with follow-up infarct on DWI. We hypothesized that CTP data, when appropriately

thresholded, could provide a reliable volumetric and spatial estimation of the follow-upinfarct.

#### 125 Materials and methods

#### 126 *Patient selection*

127 This study pooled individual patient data from seven randomized trials of endovascular thrombectomy (HERMES collaboration)<sup>2-8,20,21</sup> and from the EXTEND-IA TNK trial.<sup>22</sup> The 128 EXTEND-IA TNK trial tested the safety and efficacy of intravenous tenecteplase versus 129 alteplase prior to thrombectomy in ischemic stroke patients. The data that support the findings 130 131 of this study are available from the corresponding author upon reasonable request. The degree of reperfusion post-thrombectomy was assessed on the final angiogram using the modified 132 133 Treatment In Cerebral Infarction (mTICI) score. To best estimate the accuracy of baseline 134 CTP after endovascular reperfusion, only patients who had substantial reperfusion (defined as mTICI 2b/3, i.e. reperfusion of >50% of the affected territory) were included in this analysis. 135 136 Sensitivity analysis was performed in patients achieving mTICI 2c/3, i.e. reperfusion of all but a few distal cortical branches.<sup>23</sup> Patients were required to have technically adequate 137 138 baseline CTP and 24h DWI follow-up. The following patient characteristics were noted: age, sex, baseline NIHSS, baseline estimated ischemic core volume, hypertension, atrial 139 140 fibrillation, diabetes mellitus, blood glucose, and smoking. Ethics approval was obtained from 141 the local institutional review boards and written informed consent was obtained from patients 142 or legal representatives.

143

144 CTP post-processing

145 CTP data were post-processed using RAPID (v4.5, Research Mode) and visually checked for
146 artefacts. Ischemic core was defined as relative CBF<30% of normal brain (see online</li>
147 supplement http://stroke.ahajournals.org).

#### 149 Data co-registration and segmentation

- 150 The 24h follow-up DWI was coregistered to the baseline CTP. Hemorrhagic transformation
- 151 (HT) was graded using the ECASS classification.<sup>24</sup> Sensitivity analysis was performed
- 152 excluding patients with hemorrhagic infarction type 2 and parenchymal hematoma.

153

- 154 Assessment of volumetric and spatial agreement
- 155 The volumetric difference between CTP and DWI ischemic core was defined as DWI volume
- 156 minus CTP core volume. Magnitude of volumetric difference is also reported. CTP and DWI
- 157 lesion overlap was calculated using FSLMaths (see online supplement
- 158 <u>http://stroke.ahajournals.org</u>) and spatial agreement assessed using FSLStats and the
- 159 EvaluateSegmentation tool.<sup>25</sup> The Dice similarity coefficient was calculated to assess spatial
- agreement between CTP and DWI lesions. The positive predictive value (PPV) was used to
- assess the proportion of the initial CTP lesion that fell within the 24h diffusion lesion. Unlike
- 162 Dice, PPV is not diminished by regions of infarction at 24h that fall outside the baseline CTP
- 163 lesion, potentially reflecting infarct growth. We also used the Average Hausdorff Distance
- 164 (AVD, the average of all minimum distances between the two segmentations) to quantify
- spatial agreement.<sup>25</sup> Patients with 0ml ischemic core within the CTP coverage were included
- 166 in volumetric analyses but excluded from spatial analyses as the outcome measures were not
- 167 calculable.

- 169 Regions of apparent CTP misclassification were visually assessed for topography (white
- 170 versus grey-matter) and co-registration accuracy. The quantity of CTP lesion outside the
- 171 follow-up infarct (defined as core volume overestimation) was quantitatively trichotomized as
- 172 0-5ml, 5-10ml and >10ml. To quantitatively assess the impact of co-registration inaccuracies

173	on the outcome metrics, we segmented the ventricles of 13 HERMES patients and 56
174	EXTEND-IA TNK patients (see online supplement http://stroke.ahajournals.org).
175	
176	Statistical analysis
177	Statistical analysis was performed using SPSS (v24 IBM, Armonk, NY). Spearman
178	Correlation Coefficient $(\rho)$ was calculated for correlations between variables.

#### 180 **Results**

181 One-hundred and twenty patients with baseline CTP and 24h MRI met inclusion criteria for

this study. Follow-up imaging was performed at median 24.4h(IQR 22.0-27.8h). In

183 HERMES, 523/738(71%) patients assigned to thrombectomy had substantial reperfusion,<sup>7,8,21</sup>

and 61 had requisite imaging. On 20/March/2017, 130 stroke patients were included in the

185 EXTEND-IA TNK trial, 76/130(58%) achieved substantial angiographic reperfusion and 59

had requisite imaging. Overall, 118/120(98%) patients were treated <6h after symptom onset.

187 Only two HERMES patients had stroke onset-to-treatment time >6h (8.2 and 8.8h). Patient

188 characteristics are detailed in Table 1.

189

190 Volumetric and spatial agreement analysis

191 For the 19/120(16%) patients without detectable ischemic core within the CTP coverage, the

192 median follow-up infarct volume (and thus median volumetric difference between baseline

193 CTP ischemic core and follow-up infarct volume) was 13.1(IQR 7.9-21.3)ml. In the

remaining 101(84%) patients, the median estimated baseline ischemic core lesion volume of

195 7.8ml increased to 30.8ml on 24h DWI with a median difference of 25.4ml (Table 1). Overall,

the median volumetric difference was 25.4(IQR 10.0-63.7)ml. In sensitivity analysis

197 excluding patients with HT, the median volume difference was 20.9ml. Median volume

198	difference in the 20 patients with HT was 69.1(IQR 24.3-142.2)ml. Increased absolute
199	volumetric difference was associated with increased estimated baseline ischemic core volume
200	( $\rho$ =0.36, $p$ <0.0001, Figure 1).

The median Dice was 0.24(IQR 0.15-0.37). The median overlap of baseline and 24h lesions was 4.4(IQR 1.2-12.0)ml. However, the median PPV was 0.68(IQR 0.40-0.88). The median AVD was 3.1(IQR 1.8-5.7)mm. Data are summarized in Table 2 and results of sensitivity analysis in patients with almost complete reperfusion were similar (supplementary Table I, http://stroke.ahajournals.org). As a measure of the influence of registration accuracy on the maximum achievable spatial agreement, manual segmentation of ventricles had median Dice 0.79(IQR 0.71-0.84), median PPV 0.81(0.72-0.87), and median AVD 0.4(0.2-0.6)mm.

210 Ischemic core overestimation and expert visual qualitative assessment

211 There were 6/120(5%) patients with CTP estimated ischemic core volume larger than the 24h 212 DWI lesion volume, median volumetric difference 4.5(range 0.6-18.9)ml. Visual analysis of lesion spatial overlap indicated that 91/120(76%) patients had some region of baseline core 213 outside the 24h infarct. Apparent core overestimation was 0.1-5.0ml in 63/120(53%) patients 214 215 (median 1.1, IQR 0.3-3.1ml) and located in white-matter in 46/63 patients. There were 21/120 (18%) patients with 5-10ml core overestimation (median 6.9, IQR 5.9-8.1ml), located in 216 217 white-matter in 18/21 patients and 17/120(14%) patients had >10ml core overestimation (median 18.3, IQR 14.3-25.5ml), 14/17 located predominantly in white-matter. Nine patients 218 219 (9%) showed regions of baseline ischemic core that were not included in the follow-up infarct 220 most likely due to poor registration, as judged by the same anatomical structures being included in both lesions. While misregistration may also have contributed to ischemic core 221

- overestimation in other patients, the overrepresentation of white-matter regions wassubstantial (Figure 2).
- 224

225 Effect of time from imaging to reperfusion

226 Median time between baseline imaging and reperfusion was 114(IOR 82-159) min. CTP 227 spatial accuracy was not associated with imaging-to-reperfusion time using Dice  $(\rho = -0.08, p = 0.41)$ , AVD  $(\rho = 0.08; p = 0.43)$  or PPV  $(\rho = -0.02, p = 0.84)$ . Longer imaging-to-228 229 reperfusion time, however, was associated with an increased volumetric difference between 230 baseline ischemic core and 24h follow-up infarct. ( $\rho$ =0.2, p=0.05, Figure 3). In spatial analysis, there was no significant difference in core overestimation between the 0-90min, 90-231 232 180min or >180min imaging-to-reperfusion time subgroups (Figure 4). The median core 233 overestimation in spatial analysis was 2.2(IQR 0.6-7.4)ml for 0-90min, 2.9(IQR 0.6-6.8)ml 234 for 90-180min, and 7.4(IQR 3.5-17.8)ml for >180min subgroups (p=0.03 for 0-90 vs. 235 >180min and p=0.03 for 90-180 vs. >180min). The median volume difference was 25.4(IQR 236 6.0-35.7)ml for 0-90min, 22.8(IQR 11.2-51.3)ml for 90-180min, and 60.0(IQR 21.1-91.7)ml 237 for >180min subgroups.

238

#### 239 **Discussion**

This study comparing baseline estimated ischemic core using a CTP-CBF threshold <30% of</li>
normal brain has demonstrated moderate spatial and volumetric agreement with follow-up
DWI lesion. Volumetric overestimation of the ischemic core was rare. A degree of false
positive core segmentation was detected in 76% of patients using spatial analysis, but was
>10ml in only 14% and co-registration inaccuracy may have also contributed. Most patients
that showed quantitative core overestimation by CTP had false positive areas in white-matter

adjacent to the lesion. Interestingly, there was no evidence that spatial and volumetric

247 accuracy was reduced in patients with shorter imaging-to-reperfusion time.

248

Some previous studies of CTP ischemic core segmentation accuracy have used
contemporaneous diffusion MRI as the reference standard. CBF-based thresholds consistently
outperformed cerebral blood volume based thresholds.<sup>26-28</sup> However, obtaining both CT and
MRI before intervention is impractical in the current era of fast endovascular workflow. There
is also potential for partial reversal of diffusion lesions with rapid reperfusion,<sup>29</sup> although
reversal is uncommon when a sufficiently low apparent diffusion contrast threshold is used to
define ischemic core.<sup>30</sup>

256

We have taken an alternative approach to CTP accuracy assessment and studied follow-up 257 diffusion lesions in patients with early reperfusion. This has practical advantages, but its 258 259 accuracy depends on the modality of imaging, the time between CTP and reperfusion (in 260 which infarct growth can continue), and the completeness of reperfusion. Voxel-based 261 subanalysis in the MR CLEAN database using Philips CTP analysis software (Philips Medical Systems BV, Best, The Netherlands) suggested that CTP misclassified a considerable amount 262 of the ischemic core volume compared to follow-up infarct (median 34ml).<sup>17</sup> The different 263 264 processing software and thresholds for infarction (based on cerebral blood volume) 265 substantially differed from the processing pathway and relative CBF<30% threshold applied 266 in RAPID. Large differences in CTP analysis results between software packages have been demonstrated previously.<sup>31,32</sup> In addition, ischemic core volumes were considerably larger in 267 268 MR CLEAN than in our study (median 49.7ml vs. 7.8ml) and the difference in results 269 supports our finding that increased baseline ischemic core volume is associated with increased volumetric difference compared to follow-up infarct volume. RAPID has been shown to more 270

accurately estimate the follow-up infarct volume than other imaging packages<sup>33,34</sup> and was 271 used in SWIFT PRIME<sup>5</sup>, EXTEND-IA<sup>3</sup>, DAWN<sup>9</sup> and DEFUSE3<sup>10</sup>. A recent subanalysis of 272 the SWIFT PRIME trial<sup>35</sup> using RAPID showed good volumetric accuracy in predicting the 273 follow-up infarct in acute stroke patients. The median baseline ischemic core volume in that 274 275 study was smaller than in our population (4 (IQR 0-13)ml versus 7.8 (IQR 2-19)ml, as was 276 the median follow-up infarct volume (18.7 (IQR 8.9-48.9)ml versus 30.8 (IQR 14.9-75.2)ml. Predictably, these smaller infarcts led to smaller volumetric inaccuracies in SWIFT PRIME 277 278 (14.8 [IQR 4.9-33.7]ml) than in our study (25.4 [IQR 10.0-63.7]ml).

279

280 Superficially, the spatial agreement of baseline CTP ischemic core and follow-up infarct with 281 a Dice co-efficient of 24% appears poor. This might be partially explained by the limitations 282 of co-registering different imaging modalities. Also, sensitivity analysis demonstrated greater 283 inaccuracy in patients who developed HT and associated edema which also impacted the 284 spatial agreement. However, the trend to increased volumetric difference with increasing 285 imaging-to-reperfusion time supports a contribution of interval infarct growth. Infarct growth 286 (which can occur despite endovascular reperfusion because of delay between imaging and 287 reperfusion or incomplete reperfusion) lowers Dice but is unrelated to CTP core segmentation accuracy. When the potential effect of infarct growth is accounted for using the PPV, a 288 289 median 68% of the baseline CTP ischemic core fell within the follow-up infarct. This should 290 be viewed in the context of the 81% precision achieved when comparing ventricle 291 segmentations, which provides an estimate of the best possible performance allowing for co-292 registration inaccuracies. Both contemporaneous DWI and follow-up infarct approaches 293 involve registration of DWI to CT, which has inherent inaccuracies due to echoplanar image 294 distortion and differing slice thicknesses.

295

In this study, the estimated ischemic core volume on baseline CTP was generally smaller than
the infarct volume as shown on the 24h follow-up MRI scan. This contrasts with previous
studies suggesting that CTP may overestimate the final infarction, leading to concerns about
unwarranted exclusion of patients from reperfusion therapies.<sup>19,36</sup> Only 6 patients had smaller
infarct volumes on 24h DWI than on baseline CTP.

301

302 There are several potential reasons for larger infarct volumes at 24h than were estimated at 303 baseline. The rCBF threshold of <30% used was specifically selected to increase specificity at the cost of sensitivity.<sup>37</sup> A RAPID rCBF threshold of <38% improves volumetric agreement, 304 but substantially overestimates core in some patients. Hence the 30% threshold was chosen to 305 306 reduce the risk of unwarranted exclusion of patients from treatment. There was potential for 307 interval infarct growth in the median 114 minutes between imaging and reperfusion. Notably, even the subgroup with <90min of imaging to reperfusion time generally had smaller CTP 308 309 volumes compared to DWI follow-up lesion volumes. There was also potential for infarct 310 growth in regions that remained hypoperfused as mTICI 2b only requires restoration of flow 311 to >50% of the affected territory. However, patients with almost complete (mTICI 2c/3) reperfusion had very similar volumetric differences. Vasogenic edema also develops and, 312 while not as pronounced at 24h as at 3-5 days, may inflate the measured infarct volume. We 313 314 acknowledge that distinguishing the effect of interval infarct growth and edema from core 315 underestimation by CTP is challenging.

316

In visual assessment of reasons for spatial inaccuracies, almost all the patients had estimated
CTP core in white-matter regions that fell outside the follow-up infarct at 24h. While these
only amounted to >10ml in 14% of patients, the accurate classification of tissue viability in
white-matter should be a focus of future attempts to improve the accuracy of CTP ischemic

321 core segmentation. The challenges of quantitatively different CBF and tolerance of ischemic
322 insult in grey and white-matter are well known and the presence of old established ischemic
323 damage as well as leukoaraiosis exacerbates this with further reductions in CBF.<sup>38</sup> Robust
324 automated grey/white segmentation on CT would be required to implement differential CBF
325 thresholds based on tissue type into current processing pipelines, and this remains
326 challenging.

327

328 A limitation of this analysis is the potential for infarct growth beyond 24h. It is known that 329 ischemic core continues to evolve in the days after stroke onset, although true expansion into 330 previously unaffected territory is less likely after substantial reperfusion, as was required in this study.<sup>39</sup> However, all time points for assessment have limitations. Later assessment at 5 331 days, e.g. in DEFUSE2<sup>40</sup>, is at the of peak of edema and overestimates the true infarct 332 333 volume. At 90 days there is atrophy which underestimates the true infarct volume. Our results apply to one specific CTP rCBF threshold processed with RAPID software and would differ 334 with other thresholds and likely with other software.<sup>31,32</sup> Patients included in the HERMES 335 336 and EXTEND-IA TNK database had relatively small ischemic core volumes at baseline, 337 despite broad inclusion criteria in most of the contributing trials. MR CLEAN, ESCAPE, REVASCAT and EXTEND-IA TNK had no upper limit on core volume, EXTEND-IA 338 339 allowed up to 70ml and SWIFT PRIME up to 50ml. The distribution of core volumes in this 340 analysis was similar to that in DAWN and DEFUSE3 which supports the generalizability of 341 our data. However, this analysis provides limited information on the accuracy of ischemic core volume prediction in patients with larger baseline ischemic core which may differ, based 342 343 on the observed association between baseline infarct volume and volumetric discrepancy.

344

#### 345 Conclusion

346 CTP estimated ischemic core volumes were substantially smaller than follow-up DWI infarct 347 lesions at 24h, particularly in patients with longer imaging to reperfusion times. Despite effective endovascular reperfusion, this may have resulted, at least in part, from infarct 348 349 growth between CTP and reperfusion or subsequent infarct growth because of incomplete 350 reperfusion or HT. This presents a methodological challenge for ischemic core validation studies. Detailed analysis revealed core overestimation predominantly in white-matter regions 351 352 that should be the target of future efforts to improve CTP ischemic core accuracy. 353 Importantly, volumetric overestimation of ischemic core by CTP was rare. Contrary to previous literature, we did not find that shorter imaging-to-reperfusion time was associated 354 355 with volumetric or spatial overestimation of core volume using CTP. 356 357 Sources of funding 358 None 359 360 Disclosures CM has consulted for Stryker and the Dutch Heart Foundation (paid to institution). HM is 361 founder and shareholder of Nico-lab. AvdL has consulted for Stryker and reports grants to his 362 363 institution from Penumbra. WvZ has consulted for Stryker and Cerenovus (paid to 364 institution). JS is an employee of the University of California that has patent rights on 365 retrieval devices for stroke; has served as an unpaid site investigator in multicenter trials 366 sponsored by Medtronic, Stryker, and Neuravi for which the UC Regents received payments 367 on the basis of clinical trial contracts for the number of subjects enrolled; has consulted for 368 Medtronic, Stryker, and Neuravi and has received stock options from Rapid Medical for services as a consultant. TJ has consulted for Stryker Neurovascular as PI for the DAWN 369

370 trial; has consulted for Fundacio Ictus as member of the Executive Committee RACECAT trial; has served as advisor for Silk Road, Anaconda, Route92, FreeOX Biotech, and Blockade 371 372 Medical; has served in the Data Safety Monitoring Board of Cerenovus. PW has consulted for Microvention and Stryker and his institution received a grant from Microvention. KM reports 373 374 grants to his institution for the PISTE trial from the Stroke Association, the NIHR Health 375 Technology Assessment programme, Medtronic and Codman. MG has a licensing agreement with GE Healthcare for further development of systems of efficient stroke diagnosis. GA 376 377 reports research support from the NIH(U01NS092076, 1U10NS086487), equity interest in 378 iSchemaView and consulting fees from Medtronic and iSchemaView. AD has consulted for Medtronic; reports a research grant by Medtronic; reports engagements as lecturer for 379 380 Medtronic. MH reports a research grant from Medtronic; reports stock ownership in Calgary 381 Scientific Inc. AD reports honoraria for CME events from Medtronic. PM reports unrestricted 382 grants to his institution from Medtronic, Stryker and Codman Johnson and Johnson, and has 383 consulted for Codman Johnson and Johnson, and Microvention. GD reports speaking 384 engagements with Boehringer Ingelheim. SD reports a research grant from NHMRC 385 Australia.

387	References			
389	1.	Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, et al. Magnetic-		
390		resonance-imaging profiles predict clinical response to early reperfusion. Ann neurol.		
391		2006;60:508-517		
392	2.	Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al.		
393		A randomized trial of intraarterial treatment for acute ischemic stroke. NEJM.		
394		2015;372:11-20		
395	3.	Campbell BCV, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al.		
396		Endovascular therapy for ischemic stroke with perfusion-imaging selection. NEJM.		
397		2015;372:1009-1018		
398	4.	Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al.		
399		Randomized assessment of rapid endovascular treatment of ischemic stroke. NEJM.		
400		2015;372:1019-1030		
401	5.	Saver JL, Goyal M, Bonafe A, Diener H-C, Levy EI, Pereira VM, et al. Stent-retriever		
402		thrombectomy after intravenous t-PA vs. t-PA alone in stroke. NEJM. 2015;372:2285-		
403		2295		
404	6.	Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al.		
405		Thrombectomy within 8h after symptom onset in ischemic stroke. NEJM.		
406		2015;372:2296-2306		
407	7.	Bracard S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, Moulin T, et al.		
408		Mechanical thrombectomy after intravenous alteplase versus alteplase alone after		
409		stroke (THRACE). Lancet Neurol.15:1138-1147		
410	8.	Muir KW, Ford GA, Messow C-M, Ford I, Murray A, Clifton A, et al. Endovascular		
411		therapy for acute ischaemic stroke. JNNP. 2017;88:38-44.		

412	9.	Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al.
413		Thrombectomy 6-24h after stroke with a mismatch between deficit and infarct. <i>NEJM</i> .
414		2018;378:11-21
415	10.	Albers GW, Lansberg MG, Kemp S, Tsai JP, Lavori P, Christensen S, et al.
416		Thrombectomy for Stroke at 6-16h with Selection by Perfusion Imaging. NEJM.
417		2018;378:708-718.
418	11.	Borst J, Berkhemer OA, Roos YB, van Bavel E, van Zwam WH, van Oostenbrugge
419		RJ, et al. Value of CTP-based patient selection for intra-arterial acute ischemic stroke
420		treatment. Stroke. 2015;46:3375-3382
421	12.	Campbell BC, Weir L, Desmond PM, Tu HT, Hand PJ, Yan B, et al. CTP improves
422		diagnostic accuracy and confidence in acute ischaemic stroke. JNNP. 2013;84:613-
423		618.
424	13.	Campbell BCV MC, Menon B, Bracard S, Hill MD, Muir K, et al. Prognostic and
425		treatment impact of penumbral imaging in pooled analysis of randomized trials of
426		endovascular stent thrombectomy. ESJ. 2017;2:6.
427	14.	Wintermark M, Reichhart M, Thiran JP, Maeder P, Chalaron M, Schnyder P, et al.
428		Prognostic accuracy of cerebral-blood-flow measurement by perfusion-CT. Ann
429		Neurol. 2002;51:417-432
430	15.	Campbell BCV, Christensen S, Levi CR, Desmond PM, Donnan GA, Davis SM, et al.
431		Comparison of CTP and MRI perfusion-diffusion mismatch in ischemic stroke.
432		Stroke. 2012;43:2648-2653
433	16.	Fahmi F, Marquering HA, Streekstra GJ, Beenen LF, Janssen NN, Majoie CB, et al.
434		Automatic detection of CTP datasets unsuitable for analysis due to head movement of
435		acute ischemic stroke patients. J Healthcare Engineering. 2014;5:67-78

- 436 17. Geuskens RR, Borst J, Lucas M, Boers AM, Berkhemer OA, Roos YB, et al.
- 437 Characteristics of misclassified CTP ischemic core in patients with acute ischemic
  438 stroke. *PLoS One*. 2015;10:e0141571
- 439 18. Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, et al. User-guided 3D
- 440 active contour segmentation of anatomical structures. *NeuroImage*. 2006;31:1116-
- 441 1128
- d'Esterre CD, Boesen ME, Ahn SH, Pordeli P, Najm M, Minhas P, et al. Timedependent CTP thresholds for patients with acute ischemic stroke. *Stroke*.
- 444 2015;46:3390-3397
- 445 20. Kakuda W, Abo M. [intravenous administration of tPA beyond 3h of the onset of
- 446 acute ischemic stroke -- MRI-based decision making]. *Brain Nerve*. 2008;60:1173447 1180
- 448 21. Goyal M, Menon BK, van Zwam WH, Dippel DWJ, Mitchell PJ, Demchuk AM, et al.
- 449 Endovascular thrombectomy after large-vessel ischaemic stroke. *Lancet*.387:1723-
- 450 1731
- 451 22. Campbell BC, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Yan B, et al.
- 452 Tenecteplase versus alteplase before endovascular thrombectomy. *IJS*.
- 453 2017:1747493017733935
- 454 23. Goyal M, Fargen KM, Turk AS, Mocco J, Liebeskind DS, Frei D, et al. 2c or not 2c:
- 455 Defining an improved revascularization grading scale and the need for standardization
- 456 of angiography outcomes in stroke trials. *JNIS*. 2014;6:83-86
- 457 24. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, Von Kummer R, et al. Intravenous
- 458 thrombolysis with recombinant tissue plasminogen activator for acute hemispheric
- 459 stroke. *JAMA*. 1995;274:1017-1025

460	25.	Taha AA, Hanbury A. Metrics for evaluating 3D medical image segmentation. BMC
461		Medical Imaging. 2015:15:29

- 462 26. Kamalian S, Kamalian S, Konstas AA, Maas MB, Payabvash S, Pomerantz SR, et al.
- 463 CTP mean-transit-time maps optimally distinguish benign oligemia from true "at-risk"
- 464 ischemic penumbra, but thresholds vary by postprocessing technique. *AJNR*.
- 465 2012;33:545-549
- 466 27. Bivard A, Levi C, Spratt N, Parsons M. Perfusion-CT in acute stroke. *Radiology*.
  467 2013;267:543-550
- 468 28. Campbell BC, Christensen S, Levi CR, Desmond PM, Donnan GA, Davis SM, et al.
- 469 Cerebral-blood-flow is the optimal CT-perfusion parameter for assessing infarct core.
- 470 *Stroke*. 2011;42:3435-3440
- 471 29. Labeyrie MA, Turc G, Hess A, Hervo P, Mas JL, Meder JF, et al. Diffusion lesion
  472 reversal after thrombolysis. *Stroke*. 2012;43:2986-2991
- 473 30. Kidwell CS, Saver JL, Mattiello J, Starkman S, Vinuela F, Duckwiler G, et al.
- 474 Thrombolytic reversal of acute human cerebral ischemic injury shown by
- diffusion/perfusion MRI. Ann Neurol. 2000;47:462-469
- 476 31. Kudo K, Sasaki M, Yamada K, Momoshima S, Utsunomiya H, Shirato H, et al.
- 477 Differences in CT-perfusion maps generated by different commercial software.
- 478 *Radiology*. 2010;254:200-209
- 479 32. Fahmi F, Marquering HA, Streekstra GJ, Beenen LFM, Velthuis BK, VanBavel E, et
- 480 al. Differences in CT-perfusion summary maps for patients with acute ischemic stroke
- 481 generated by 2 software packages. *AJNR*. 2012;33:2074-2080
- 482 33. Austein F, Riedel C, Kerby T, Meyne J, Binder A, Lindner T, et al. Comparison of
- 483 perfusion-CT software to predict the final infarct volume after thrombectomy. *Stroke*.
- 484 2016;47:2311-2317

- 485 34. Kudo K, Christensen S, Sasaki M, Ostergaard L, Shirato H, Ogasawara K, et al.
- 486 Accuracy and reliability assessment of CT and MR-perfusion analysis software using
  487 a digital phantom. *Radiology*. 2013;267:201-211
- 488 35. Albers GW, Goyal M, Jahan R, Bonafe A, Diener HC, Levy EI, et al. Ischemic core
- and hypoperfusion volumes predict infarct size in SWIFT PRIME. *Ann neurol.*

490 2016;79:76-89

- 491 36. Boned S, Padroni M, Rubiera M, Tomasello A, Coscojuela P, Romero N, et al.
- 492 Admission CT-perfusion may overestimate initial infarct core. *JNIS*. 2016
- 493 37. Cereda CW, Christensen S, Campbell BC, Mishra NK, Mlynash M, Levi C, et al. A
- benchmarking tool to evaluate CTP infarct core predictions against a DWI standard.
- 495 *JCBFM*. 2016;36:1780-1789
- 38. Zijdenbos AP, Dawant BM, Margolin RA, Palmer AC. Morphometric analysis of
  white-matter-lesions in MRI. *IEEE trans medical imaging*. 1994;13:716-724
- 498 39. Lansberg MG, O'Brien MW, Tong DC, Moseley ME, Albers GW. Evolution of
- 499 cerebral infarct volume assessed by diffusion-weighted MRI. *Arch Neurol*.
- 500 2001;58:613-617
- Wheeler HM, Mlynash M, Inoue M, Tipirneni A, Liggins J, Zaharchuk G, et al. Early
  diffusion-weighted-imaging and perfusion-weighted-imaging lesion volumes forecast
- 503 final infarct size in DEFUSE2. *Stroke*. 2013;44:681-685

506	Figure legends
507	

508 Figure 1. Scatter-plots of (a) baseline core volume and 24h follow-up infarct volume ( $\rho$ =0.65) 509 (b) baseline core volume and absolute volumetric difference ( $\rho$ =0.07).

510

511 Figure 2. An 89-year-old man with right M1 segment middle cerebral artery occlusion. A)

512 Cerebral blood flow map with B) RAPID estimation of ischemic core. C) 24h diffusion MRI
513 after successful endovascular reperfusion indicating that the basal ganglia core was correctly
514 identified on CTP, but there was core overestimation in adjacent white-matter. D) FLAIR
515 indicating leukoaraiosis.

516

Figure 3. Scatter-plot of the association between imaging-to-reperfusion time and volumetric
difference (calculated as 24h follow-up infarct volume – baseline infarct volume).

519

Figure 4. Ischemic core overestimation (spatial analysis) by imaging-to-reperfusion time A)
Scatter-plot. B) Boxplot for the 0-90min, 90-180min and >180min imaging-to-reperfusion
time subgroups. C) Volumetric difference between baseline estimated ischemic core and
follow-up infarct volume in three subgroups by imaging-to-reperfusion time. Negative
volume differences on the Y-axis indicate 24h volumes higher than baseline estimated core
volumes.

- 527
- 528

## 529 Tables

530

# 531 Table 1. Patient characteristics [N=120]

Mean age, yr(SD)	69.6(12.9)
Sex, n(%) male	59(49)
Median baseline NIHSS*(IQR)	16(14-21)
Hypertension, n(%)	82(69)
Atrial fibrillation, n(%)	43(36)
Diabetes mellitus, n(%)	16(13)
Median glucose blood level, mmol/l(IQR)	6.4(5.6-7.4)
Smoking history, n(%)	39(35)
Median baseline core volume, ml(IQR)	7.8(1.8-19.9)
Median 24h follow-up infarct volume, ml(IQR)	30.8(14.9-67.6)
Median volumetric difference, ml(IQR)	25.4(10.0-63.7)

- <sup>\*</sup>National Institutes of Health Stroke Scale
- 533

Median onset-to-imaging time, min(IQR) [N=117]	109(71-152)
Median imaging-to-reperfusion time, min(IQR) [N=117]	114(82-159)
Median onset-to-reperfusion time, min(IQR) [N=117]	233(187-288)
Median Dice similarity coefficient(IQR) [N=101]	0.24(0.15-0.37)
Median Precision(IQR) [N=101]	0.68(0.40-0.88)
Median Average Hausdorff Distance, mm(IQR) [N=101]	3.1(1.8-5.7)

## 534 Table 2. Procedural and outcome data